Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry
Tatiana Cobo-Ibáñez, Ivan Castellví, Ana Pros, Marta Domínguez-Álvaro, Laura Nuño-Nuño, Julia Martínez-Barrio, Vega Jovaní, Fredeswinda Romero-Bueno, Esther Ruiz-Lucea, Eva Tomero, Ernesto Trallero-Araguás, Javier Narváez, Jordi Camins-Fàbregas, Alberto Ruiz-Román, Jesús Loarce-Martos, Susana Holgado-Pérez, V Miguel Flores-Rodríguez, Francisca Sivera, Carolina Merino-Argumanez, Antonio Juan-Mas, Irene Altabás-González, María Martín-López, Joaquín María Belzunegui-Otano, Carmen Carrasco-Cubero, Mercedes Freire-González, Iñigo Rúa-Figueroa, Nuria Lozano-Rivas, Julio David Suarez-Cuba, Olga Martínez, Rafaela Ortega-Castro, Patricia Alcocer, Alejandro Gómez-Gómez, Olga Sánchez-Pernaute, José Luis Tandaipan, Irene Carrión-Barberà, Chamaida Plasencia-Rodríguez, Oihane Ibarguengoitia-Barrena, Paola Vidal-Montal, Vera Ortiz-Santamaria, Noemi Garrido-Puñal, Anne Riveros, Esmeralda Delgado-Frías, Juan Miguel López-Gómez, Carmen Barbadillo, José María Pego-Reigosa, Beatriz E. Joven-Ibáñ..
{"title":"Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry","authors":"Tatiana Cobo-Ibáñez, Ivan Castellví, Ana Pros, Marta Domínguez-Álvaro, Laura Nuño-Nuño, Julia Martínez-Barrio, Vega Jovaní, Fredeswinda Romero-Bueno, Esther Ruiz-Lucea, Eva Tomero, Ernesto Trallero-Araguás, Javier Narváez, Jordi Camins-Fàbregas, Alberto Ruiz-Román, Jesús Loarce-Martos, Susana Holgado-Pérez, V Miguel Flores-Rodríguez, Francisca Sivera, Carolina Merino-Argumanez, Antonio Juan-Mas, Irene Altabás-González, María Martín-López, Joaquín María Belzunegui-Otano, Carmen Carrasco-Cubero, Mercedes Freire-González, Iñigo Rúa-Figueroa, Nuria Lozano-Rivas, Julio David Suarez-Cuba, Olga Martínez, Rafaela Ortega-Castro, Patricia Alcocer, Alejandro Gómez-Gómez, Olga Sánchez-Pernaute, José Luis Tandaipan, Irene Carrión-Barberà, Chamaida Plasencia-Rodríguez, Oihane Ibarguengoitia-Barrena, Paola Vidal-Montal, Vera Ortiz-Santamaria, Noemi Garrido-Puñal, Anne Riveros, Esmeralda Delgado-Frías, Juan Miguel López-Gómez, Carmen Barbadillo, José María Pego-Reigosa, Beatriz E. Joven-Ibáñ..","doi":"10.1186/s13075-024-03471-x","DOIUrl":null,"url":null,"abstract":"To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p < 0.05), except for MYOACT muscular and creatine phosphokinase, for which no differences were recorded in ASA-positive patients. No differences were found between incident and prevalent cases for measures of damage. Values for the physical component of the SF-12 were higher in the prevalent cases (p < 0.05). The multivariate model was initially significant overall for the main activity outcomes. Positivity to ASAs was positively and negatively associated with the MYOACT index and MMT-8, respectively (p < 0.05), although no association was recorded with PhGA and extramuscular activity. Prevalent cases were negatively associated with the main outcomes of activity, except with MMT-8, for which the association was positive (p < 0.05). The main activity outcomes validated in polymyositis and dermatomyositis could also be used in other subtypes of IIM, such as antisynthetase syndrome. Recent diagnosis is associated with greater disease activity, as assessed based on these activity outcomes. PhGA and extramuscular activity are not modified by ASA positivity, thus supporting their preferred use for assessing treatment response in IIM with ASAs.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"11 3 1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthritis Research & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13075-024-03471-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
To evaluate the main outcomes of disease activity and their association with other measures of activity, damage, and quality of life in patients with idiopathic inflammatory myopathy (IIM) according to time since diagnosis and positivity to antisynthetase autoantibodies (ASAs). Cross-sectional multicenter study within the Spanish Myo-Spain registry. Cases were classified as incident (≤ 12 months since diagnosis) and prevalent. The main outcomes of disease activity were the Myositis Disease Activity Assessment visual analogue scale (MYOACT), the Manual Muscle Test 8 (MMT-8), physician global activity (PhGA), and extramuscular activity. Other measures of activity, damage, and quality of life included patient global disease activity, MYOACT muscular, creatine phosphokinase, Health Assessment Questionnaire, physician and patient global damage, global damage of the Myositis Damage Index, and the 12-item Short-Form Health Survey (SF-12). We analyzed associations using a multivariate generalized linear model and a simple linear regression model. A total of 554 patients with different diagnostic subgroups of IIM were included (136 incident and 418 prevalent cases), with 215 ASA-positive patients (58 incident and 157 prevalent cases). All measures of disease activity were higher in the incident cases (p < 0.05), except for MYOACT muscular and creatine phosphokinase, for which no differences were recorded in ASA-positive patients. No differences were found between incident and prevalent cases for measures of damage. Values for the physical component of the SF-12 were higher in the prevalent cases (p < 0.05). The multivariate model was initially significant overall for the main activity outcomes. Positivity to ASAs was positively and negatively associated with the MYOACT index and MMT-8, respectively (p < 0.05), although no association was recorded with PhGA and extramuscular activity. Prevalent cases were negatively associated with the main outcomes of activity, except with MMT-8, for which the association was positive (p < 0.05). The main activity outcomes validated in polymyositis and dermatomyositis could also be used in other subtypes of IIM, such as antisynthetase syndrome. Recent diagnosis is associated with greater disease activity, as assessed based on these activity outcomes. PhGA and extramuscular activity are not modified by ASA positivity, thus supporting their preferred use for assessing treatment response in IIM with ASAs.
期刊介绍:
Established in 1999, Arthritis Research and Therapy is an international, open access, peer-reviewed journal, publishing original articles in the area of musculoskeletal research and therapy as well as, reviews, commentaries and reports. A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care. Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.